2ONE Labs Announces PMTA Submission Update, Nicotine Pouch Products Receive FDA 'Acceptance' Again

Dec.05.2024
2ONE Labs Announces PMTA Submission Update, Nicotine Pouch Products Receive FDA 'Acceptance' Again
Nicotine pouch brand 2ONE Labs Inc. has announced that it has received an 'Acceptance' notification from FDA for its second Pre-market Tobacco Application (PMTA) submission for the 2ONE® nicotine-flavored products.

LAKE TAHOE, Nev., Dec. 03, 2024-- 2ONE Labs Inc., is pleased to have received 'Acceptance' of a second Premarket Tobacco Product Application (PMTA) for additional flavored 2ONE® nicotine product styles submitted to the U.S. Food and Drug Administration (FDA).

 

Welcoming receipt of this additional FDA 'Acceptance' notification, Vincent Schuman, CEO of 2ONE Labs, said: "Our strategy has always been to maintain a steady flow of supportable and responsible PMTA submissions for the 2ONE® nicotine pouch brand that reflect current adult consumer product demands. Our timely PMTA filings with the FDA reflect our company's commitment to remaining at the forefront of product innovation in the nicotine pouch marketplace."

 

"As with our previously 'Accepted' 2ONE® PMTA submission, this application will move forward to the next stage of FDA review. 2ONE Labs aims to fund these submissions to a successful 'Authorization' by FDA. Our wholesale, retail and sponsorship partners should take confidence in this additional ‘Acceptance’ as a reflection of our ability to manage and navigate the complex PMTA process, and of our commitment to supporting the 2ONE® brand in the US market."

 

Schuman added: "2ONE® Tobacco-Free nicotine pouches are for adult users (21+), who want to switch from cigarettes, cigars or traditional oral tobacco chewing products."

 

Source: GLOBE NEWSWIRE

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Spain’s Competition Authority Questions Disposable Vape Ban
Spain’s Competition Authority Questions Disposable Vape Ban
Spain’s National Commission on Markets and Competition (CNMC) has issued an opinion on the draft reform of the Tobacco Law proposed by the Ministry of Health, urging reconsideration of several measures. These include a proposed ban on disposable e-cigarettes and the full alignment of vaping products with traditional tobacco regulation.
Dec.17 by 2FIRSTS.ai
South Korea’s Parliament Reconsiders Bill to Regulate Synthetic Nicotine as Tobacco
South Korea’s Parliament Reconsiders Bill to Regulate Synthetic Nicotine as Tobacco
South Korea’s National Assembly is once again reviewing a bill to classify synthetic nicotine as a tobacco product under the Tobacco Business Act. The proposal aims to close regulatory loopholes that allow untaxed, unregulated nicotine liquids — often used by minors — to circulate freely. Lawmakers expect the bill to pass during the current session amid growing public and civic pressure.
Nov.26 by 2FIRSTS.ai
UK’s Nationwide Crackdown Seizes 111,000 Illegal Vapes in “Machinize 2” Operation
UK’s Nationwide Crackdown Seizes 111,000 Illegal Vapes in “Machinize 2” Operation
UK police have carried out a nationwide crackdown under Operation Machinize 2, targeting illegal vapes, counterfeit goods, and grey-market businesses. Raids on more than 2,700 premises led to 924 arrests and the seizure of 111,000 illegal vapes, 70kg of cannabis, 4.5m cigarettes, and £10.7m in proceeds.
Nov.11 by 2FIRSTS.ai
84% of Britons Back Regulation of Nicotine Pouches, Survey Finds
84% of Britons Back Regulation of Nicotine Pouches, Survey Finds
A Northerner survey finds 84% of Britons support regulating nicotine pouches and 82% back a licensing scheme for vape sales, aligning with the Tobacco and Vapes Bill to improve consumer safety and youth protection.
Nov.06 by 2FIRSTS.ai
RFK Jr. Says Public Should Not Follow His Personal Use of Zyn Nicotine Pouches
RFK Jr. Says Public Should Not Follow His Personal Use of Zyn Nicotine Pouches
According to People, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said in an interview with The Atlantic that although he frequently uses Zyn nicotine pouches, he does not recommend that Americans imitate his personal habits. His use of nicotine products has drawn renewed attention, alongside ongoing scrutiny of his broader health-related positions.
Dec.04
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai